Ionis Pharmaceuticals has received $40 million in milestone earnings from Biogen following Japanese regulatory approval of the price of Spinraza, Biogen’s treatment for spinal muscular atrophy.
So far, Ionis has earned more ... Read more
Spinal muscular atrophy (SMA) is a neuromuscular disorder, characterized mainly by progressive muscle loss. Physical therapy plays an important role in SMA treatment; however, there are many myths out ... Read more
Infants with Spinal Muscular Atrophy (SMA) who do not yet show symptoms experience numerous benefits from Spinraza (nusinersen) treatment, according to data that Biogen will present at the Cure SMA 2017 ... Read more
Becoming a parent is always an overwhelming and sometimes daunting experience. This is amplified when you discover that your child has a health condition like spinal muscular atrophy (SMA). Cure SMA ... Read more
A recent survey showed that spinal muscular atrophy (SMA) patients and their families are generally supportive of genetic screening program for early detection of SMA. However, they still have ... Read more
Cure SMA, an organization dedicated to the treatment and cure of spinal muscular atrophy (SMA), has launched a booklet addressing some of the broader questions about insurance coverage that ... Read more